Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 213-227

  Haspinger, Eva Regina ^a   Agustoni, Francesco ^a   Torri, Valter ^b   Gelsomino, Francesco ^a   Platania, Marco ^a   Zilembo, Nicoletta ^a   Gallucci, Rosaria ^a   Garassino, Marina Chiara ^a   Cinquini, Michela ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

EGFR TKI; First line; NSCLC; Review

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DISEASE COURSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; EXON; GENE; GENE DELETION; GENE MUTATION; HAZARD RATIO; HUMAN; HYPERTRANSAMINASEMIA; L858R GENE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MUTATION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84926085714     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.11.005     Document Type: Review

References (47)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. Cancer J Clin 2010, 60:277-300.
2. Alvarez M., Roman E., Santos E.S., Raez L.E. New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther 2007, 7:1423-1437.
3. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
4. Schiller J.H., Harrington D., Belani C.P., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
5. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
6. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
7. Pérez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
8. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
9. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
10. Lund-Iversen M., Kleinberg L., Fjellbirkeland L., Helland Å., Brustugun O.T. Clinicalpathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol 2012, 7:1471-1473.
11. De Pas T., Toffalorio F., Manzotti M., et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011, 6:1895-1901.
12. Wang H., Huang J., Yu X., et al. Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. J Cancer Res Clin Oncol 2014, [Epub ahead of print].
13. Fukuoka M., Wu Y.L., Thongprasert S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
14. Crinò L., Cappuzzo F., Zatloukal P., et al. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008, 26:4253-4260.
15. Lilenbaum R., Axelrod R., Thomas S., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008, 26:863-869.
16. Morère J.F., Bréchot J.M., Westeel V., et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 2010, 70:301-307.
17. Agarwal S., Hirsh V., Agulnik J.S., et al. A phase II study of gefitinib (G) versus carboplatin and gemcitabine (CG) in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC) and ECOG performance status (PS) 2. 2010 ASCO Annual Meeting 2010, Abs e18090.
18. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
19. Han J.Y., Park K., Kim S.W., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
20. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
21. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
22. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
23. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
24. Gridelli C., Ciardiello F., Gallo C., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol 2012, 30:3002-3011.
25. Sequist L.V., Yang J.C.H., Yamamoto N., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 20(31):3327-3334.
26. Wu Y.L., Zhou C., Hu C.P., et al. 2013 ASCO Annual Meeting. LUX-Lung 6: a randomized, open-label, phase III study of afatinib vs gemcitabine/cisplatin as first-line treatment for Asian patients with EGFR mutation-positive advanced adenocarcinoma of the lung. Lancet Oncol 2014, 1(15):1-10.
27. Higgins J.P., Altman D.G., Gotzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trial. BMJ 2011, 343.
28. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
29. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
30. Glenny A.M., Altman D.G., Song F., et al. Indirect comparisons of competing interventions. Health Technol Assess 2005, 9:1-134.
31. Sterne J.A., Egger M., Smith G.D. Systematic reviews in health care. Assessing the quality of controlled clinical trials. BMJ 2001, 323:101-105.
32. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21:2313-2324.
33. Der Simonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986, 7:177-188.
34. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
35. RevMan Review Manager 2008, The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen.
36. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269.
37. Shi Y., Zhang L., Liu X., et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomized, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013, 14(September (10)):953-961.
38. Berardi R., Santoni M., Morgese F., et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013, 21(May (6)):563-576.
39. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
40. Solca F., Dahl C., Zoephel A., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
41. http://clinicaltrials.gov/ct2/show/NCT01466660?term=lux+lung+7&rank=1 LUX-Lung 7: A Phase IIb Trial of Afatinib (BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung.
42. Goss G., Felip E., Cobo M., et al. A randomized, open-label, phase III trial of afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8) Abstract 1222O. 2014 ESMO Annual Meeting 2014.
43. Katakami N., Morita S., Yoshioka H., et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. 2014 ASCO Annual Meeting 2014.
44. Stone A.M., Bushnell W., Denne J., et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 2011, 47:1763-1771.
45. Garassino M.C., Torri V. Afatinib for lung cancer: let there be light?. Lancet Oncol 2014, 15(2):133-134.
46. Yang J.C.H., Sequist L.V., Schuler M., et al. Overall survival in patients with advanced NSCLC harbouring common (Del19/L585R) EGFR mutations: analysis of two large, open-label phase III studies of afatinib vs chemotherapy, LUX-Lung 3 and LUX-Lung 6. Abstract 8004. 2014 ASCO Annual Meeting 2014.
47. Pilotto S., Di Maio M., Peretti U., et al. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: sensitivity and meta-regression analysis of randomized trials. Crit Rev Oncol Hematol 2014, 9:135-145.